Saratoga Moderately Agrsv Bal Allc C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Saratoga Moderately Aggressive Balanced Allocation Portfolio Class C SAMCX
- NAV / 1-Day Return 12.33 / −0.65 %
- Total Assets 1.3M
-
Adj. Expense Ratio
3.170%
- Expense Ratio 1.990%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Moderate Allocation
- Investment Style Mid Blend
- Credit Quality / Interest Rate Sensitivity Medium/Moderate
- Status Open
- TTM Yield 1.63%
- Turnover 5%
USD | NAV as of Oct 08, 2026 | 1-Day Return as of Oct 08, 2026, 12:04 AM GMT+0
Morningstar’s Analysis SAMCX
Will SAMCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 91.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Vanguard Interm-Term Bond Index Adm | 18.50 | 240,472 | — |
Saratoga Large Capitalization Growth I | 16.67 | 216,606 | — |
Saratoga Large Capitalization Value I | 14.18 | 184,232 | — |
Saratoga Mid Capitalization I | 13.32 | 173,172 | — |
BNY Dreyfus Instl Pref Govt MMkt Instl | 8.95 | 116,387 | Cash and Equivalents |
Saratoga Small Capitalization I | 7.88 | 102,392 | — |
Vanguard Total Intl Stock Index Admiral | 5.64 | 73,363 | — |
Eaton Vance Glbl Macr Absolute Return I | 4.95 | 64,272 | — |
Saratoga Technology & Comm I | 4.93 | 64,103 | — |
Saratoga Health & Biotechnology I | 2.54 | 33,015 | — |